Median progression-free survival was 13.1 and 8.7 months with pembrolizumab and placebo, respectively, in the pMMR cohort (hazard ratio, 0.54).

Source: https://www.gjsentinel.com/lifestyle/health_and_wellness/adding-pembrolizumab-to-chemo-improves-survival-in-endometrial-cancer/article_329e7dd7-c41a-5860-9f91-3c68ccdfd42a.html

Notably, four out of eight or 50% of the combination patients with low PD-L1 expression, i.e., CPS scores of one to 19 experienced objective responses which is, greater than the expected rate of approximately 14% with pembrolizumab alone.

Source: https://seekingalpha.com/article/4626366-cue-biopharma-inc-cue-q2-2023-earnings-call-transcript?source=feed_all_articles